Babesiosis is an emerging tickborne malaria-like infection principally caused by Babesia microti. This infection typically resolves either spontaneously or after administration of a 7-10-day course of azithromycin plus atovaquone or clindamycin plus quinine [1, 2] . Although certain highly immunocompromised patients may respond suboptimally to these drug regimens, unlike the situation with malaria there has been no reported evidence that the cause of treatment failure is infection with drug-resistant strains of B. microti [3] . Furthermore, the emergence of drug resistance during a course of treatment for babesiosis has not been reported in humans [3] . We describe here 3 highly immunocompromised patients who received a subcurative course of azithromycin-atovaquone associated with the eventual development of resistance to this drug regimen.
METHODS
Emergence of drug resistance in B. microti was defined as the development of a microbiologic relapse (recurrent parasitemia or a marked increase in parasitemia) in association with both clinical and laboratory abnormalities indicative of active babesiosis in a patient after у28 days of uninterrupted antibabesia drug therapy and while still receiving treatment. Three patients known to the authors to have met these criteria are included in this article. Patient 2 was included in a previously published case series [3] . In the hospital, the patient was febrile and had abnormal hematologic parameters before the splenectomy (hemoglobin level, 9.3 g/dL; platelet count, 93,000/mL) that persisted postoperatively. Pathologic examination of the spleen did not show lymphoma. A peripheral blood smear on the sixth postoperative day showed B. microti (level of parasitemia, 0.5%) (Figures 1  and 2 ) that prompted review of the blood smear performed before the splenectomy, which also showed B. microti. The patient began treatment with quinine (650 mg orally 3 times a day) and clindamycin (900 mg intravenously 3 times a day) on 13 On readmission (hospitalization 2; 7-20 March 2008), the level of parasitemia was 3% (Figure 2 ). Because of unexplained granulocytopenia (200 neutrophils/mL) on that date, the patient received 2 doses of granulocyte colony stimulating factor. The relapse of babesiosis was treated with clindamycin-quinine, but quinine was discontinued 2 days later on 9 March 2008 because of intolerance and an increase in the level of parasitemia to 5.6%; atovaquone (750 mg twice a day) was started. Because of persistent fever (temperatures to 140ЊC) and continued severity of illness, he underwent red cell exchange transfusion on 12 March 2008; also on that date, azithromycin (500 mg intravenously once a day) was substituted for clindamycin. Intravenous immunoglobulin (400 mg/kg) was given on 13 March
. The patient defervesced by 17 March. The level of parasitemia fell to !0.1% on 18 March (Figure 2 ), the same day that the azithromycin dose was changed to 500 mg orally once a day.
After 31 days of azithromycin-atovaquone therapy and while still receiving this treatment, fever with rigors recurred on 11 April 2008 associated with a level of parasitemia of 3% on 14 April 2008 that increased to 8.5% five days later on 19 April 2008, the highest level that had thus far been recorded ( Figure   2 ). These events provided evidence that the strain of B. microti infecting this patient was resistant to azithromycin-atovaquone.
The patient was hospitalized again on 18 April (hospitalization 3; 18-30 April 2008). He underwent a red cell exchange transfusion on 19 April 2008. He received a variety of drugs for the babesia infection and was eventually stabilized with a multidrug regimen consisting of malarone (4 tablets daily; each tablet contained 100 mg of proguanil plus 250 mg of atovaquone), atovaquone (750 mg once a day), doxycycline (100 mg orally twice a day), and clindamycin (300 mg orally once a day). He continued receiving the malarone-containing regimen for ∼13 months until 21 May 2009, which was 18 months after the last dose of rituximab. This duration of treatment was chosen because a recent study suggested that the effects of rituximab with respect to susceptibility to severe babesiosis might last for this period of time [3] . In addition, the patient has been treated with intravenous immunoglobulin every 2-3 weeks until the present time. A diagnosis of babesiosis was made on the basis of a blood smear showing numerous parasites, and the patient was treated with atovaquone (750 mg twice a day) and azithromycin (500 mg on day 1 and then 250 mg once a day for 7 days) starting on 15 July 2005. The patient defervesced and experienced some clinical improvement; a blood smear was not done at the conclusion of the antibabesia treatment.
Two weeks after the azithromycin-atovaquone therapy was discontinued, fever (temperature to 38.9ЊC) recurred associated with chills, sweats, weakness, anorexia, and a 15-pound weight loss, as well as anemia and thrombocytopenia. She was admitted to the hospital on 16 August 2005 and was found to have numerous babesia on blood smear. She was treated with clindamycin-quinine, which resulted in a decrease in the level of parasitemia to !1% on 3 September 2005 and resolution of fever. B. microti DNA was amplified from blood. Because of the development of a generalized rash, treatment was changed on 3 September 2005 to atovaquone (750 mg twice a day) and azithromycin (500 mg on day 1 followed by 250 mg once a day); in addition, she was given repeated red blood cell transfusions and intravenous immunoglobulin because of persistent panhypogammaglobulinemia.
Evidence that the strain of B. microti infecting this patient was resistant to azithromycin-atovaquone appeared on the 49th day of treatment with this drug regimen, when the patient was readmitted to the hospital on 21 October 2005 with recurrent fever and a level of parasitemia of 30%. Two red cell exchange transfusions were performed. Various antibabesia therapies were tried sequentially, and she was eventually stabilized with a regimen of clindamycin (450 mg orally 4 times a day), doxycycline (100 mg orally twice a day), atovaquone (750 mg orally once a day), and interferon gamma (84 mg subcutaneously every other day). Blood smear and PCR results for babesia were neg- 
DISCUSSION
The recommended duration of treatment for babesiosis is 7-10 days [1, 2] , but this duration of treatment may be inadequate for patients with immunodeficiency [3] . Our experience with 3 highly immunocompromised patients clearly demonstrates the challenges of eradicating babesiosis in such patients. Each of our patients had a history of lymphoma and asplenia; 2 had received rituximab, and 1 had undergone solid organ transplant. In addition, 2 of our patients had hypogammaglobulinemia, and the third had IgG2 subclass deficiency; 1 had transient granulocytopenia. The failure of azithromycin-atovaquone therapy to eradicate babesiosis in these patients serves to highlight certain limitations of current treatment regimens that are less likely to be appreciated in nonimmunocompromised patients, in whom babesiosis may resolve spontaneously without antiparasitic drug therapy [4, 5] .
In each of our patients, babesiosis relapsed after completion of an initial course of azithromycin-atovaquone. Then, when they were re-treated with this regimen for 130 days, the patients experienced relapse while still receiving therapy ( Table 1) . The patients were compliant with taking the drugs, and none had clinical evidence of malabsorption. Therefore, we conclude that resistance to an azithromycin-atovaquone drug regimen can emerge during treatment. Whether a higher dosage of either or both of the components of this regimen could have overcome the resistance is unknown.
Infection in 2 of the patients appeared to resolve coincidently with treatment with multidrug regimens that also included atovaquone. Whether the atovaquone provided any clinical benefit in these salvage therapies is unclear, but it is possible that it contributed in an additive or synergistic manner to the treatment benefit afforded by clindamycin or proguanil [6] . In addition, it is conceivable that resistance to azithromycin-atovaquone might be observed clinically even if the actual resistance were only to the azithromycin component.
Emergence of resistance to atovaquone used as a single drug has been documented in animal models of infection using hamsters or gerbils [7, 8] . The mechanism for the development of resistance was not established. Of potential relevance to our patients, there was no evidence for the emergence of resistance to atovaquone in these animals when given in combination with a second drug.
Observations made in animal models of infection [7] [8] [9] [10] [11] [12] , which are supported by the events that occurred in the patients described in this article, also suggest that individual drugs (as well as drug combinations) either inconsistently kill the parasite or are exclusively inhibitory against B. microti. The observation that low-level parasitemia will often persist after completion of a у7-day course of antibabesial treatment in humans with apparently normal immune systems provides additional evidence in support of this hypothesis [2, 5] . Those animal studies in which drug therapy appeared to be curative for B. microti infection need to be interpreted cautiously [13] . Misleading conclusions about microbiologic cures can result from terminating experiments before recrudescence would have occurred or from assaying for persistent infection without first subjecting animals to immunosuppression [8, 10] . Thus, it is highly likely that the drug regimens currently used clinically are adjunctive to an effective immune response for the eradication of B. microti infection.
The association between persistent babesiosis and therapy with rituximab (a monoclonal antibody that depletes B cells) would seem to imply that humoral immunity is of considerable relevance to an effective host response in babesiosis [3] . Two of our patients failed to produce antibabesial IgG, and the third had only a low antibody level. The preponderance of data from animal systems indicates, however, that control of an established infection is dependent on an appropriate cellular immune response [14, 15] . Given that B cells also function as antigen-presenting cells for T cells and have other effects on T cell function, their depletion may affect cellular immune responses as well [16] .
Our study has several potential limitations. The definition of drug resistance used was more stringent than generally accepted definitions of clinical resistance in patients treated for malaria [17] ; thus, alternative definitions should be evaluated in future studies. We did not inoculate any of the B. microti strains into animals. Had this been done, it would have provided an opportunity to determine if such animal systems faithfully reproduce the clinical events that we observed. To date, however, testing for antimicrobial susceptibility in animal systems has not been standardized, and the results have not always been concordant between studies or with clinical experience [7, 8, [10] [11] [12] [13] . We also did not attempt to elucidate the molecular basis for drug resistance, an important topic for future investigation.
In summary, we have found convincing clinical evidence that B. microti may become resistant to azithromycin-atovaquone during treatment of babesiosis with this combined drug regimen. Drug resistance is likely to develop only in highly immunocompromised patients and is unlikely to become a major public health problem as with malaria [18] , because the reservoirs for this infection are rodents rather than humans, and babesia strains in rodents are not exposed to drug therapies. Although research is needed to determine the optimal therapy for highly immunocompromised patients with babesiosis, reducing the level of immunosuppression when possible would appear to be a desirable strategy.
